Meeting
2015 ASCO Annual Meeting
Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.
Authors
Annick Desjardins
Duke University Medical Center, Durham, NC
Annick Desjardins , Katherine B. Peters , Gordana Vlahovic , Dina Randazzo , Susan Boulton , Woody C Massey , Eric S Lipp , James Emmett Herndon II, Patrick Healy , Elizabeth Miller , Rashida A. Karmali , Henry S. Friedman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01954030
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2067)
DOI
10.1200/jco.2015.33.15_suppl.2067
Abstract #
2067
Poster Bd #
56
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways.
First Author: Antonio Marcilio Padula Omuro
Poster
2016 ASCO Annual Meeting
Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma.
First Author: Khe Hoang-Xuan
Poster
2016 ASCO Annual Meeting
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho
Poster
2013 ASCO Annual Meeting
Pazopanib (P) and bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors: Phase I combination study final analysis.
First Author: Sylvie Negrier